What happened? Shares of Evolent Health (NYSE: EVH) are rising sharply on Friday after the company announced better than expected fourth-quarter and full-year financial results. Evolent Health's stock was up by 6.6% as of 1:24 p.m. EST. So what During its fourth-quarter 2020 that ended on Dec. 31, Evolent Health recorded revenue of $271.9 million, representing a 15% year-over-year increase. The company's top line handily beat the Wall Street average estimate of $261.55 million. Meanwhile, the company recorded a net loss based on generally accepted accounting principles (GAAP) of $14.6 million, compared to the net loss of $198.1 million it recorded during the prior-year quarter. Analysts are often more interested in a company's non-GAAP (adjusted) bottom line, however. Image source: Getty Images. On that front, Evolent Health reported an adjusted net loss of $598 thousand and an adjusted net loss per share of $0.01, compared to the adjusted loss and adjusted loss per share of $5.8 million and $0.07 it recorded during the year-ago period. On average, analysts expected the company's non-GAAP loss per share to be $0.05. For the fiscal year 2020, Evolent Health recorded revenue of $1.02 billion and an adjusted loss per share of $0.21. These numbers compare favorably to the revenue of $1.01 billion and non-GAAP loss per share of $0.24 analysts expected. Now what Posting revenue and earnings that top analyst estimates is a great way for a company to get the attention of investors. And since this happened for Evolent Health during a year of unprecedented challenges, it is all the more impressive. Thus, it isn't surprising to see investors bidding up this healthcare stock today. 10 stocks we like better than Evolent HealthWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Evolent Health wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.Source